Selecting and validating new TB smear microscopy stains

Changing the brand of a tuberculosis (TB) smear microscopy stain can seem like a simple procurement swap. It is not. A new formulation of carbol fuchsin, acid-alcohol, methylene blue or auramine stain may change contrast, background, decolourisation, stability, staff exposure and the visibility of scanty acid-fast bacilli (AFB). The guide should therefore treat the change as a managed quality event that protects patient results while keeping work practical for busy microscopy benches.

Australian conditions add important variables. A metropolitan laboratory in Melbourne, a regional service in Townsville and a remote clinic sending specimens through Darwin face different supply, staffing and transport realities. Reagents may travel further, arrive after temperature excursions or sit in stock longer than expected. The guide should cover storage, shipment checks, backup suppliers and continuity of testing, without assuming every site has the same staffing or infrastructure.

The guide should state its purpose, scope and intended users in plain language: laboratory staff, quality managers, procurement officers and authorised signatories. Define “new brand”, “verification”, “validation”, “reference method” and “acceptance criteria”. It should explain when a new lot requires routine verification and when a different manufacturer or formulation needs fuller local validation. This prevents a purchase decision from outrunning the evidence.

Map the content to the GLI Quality Tool’s four-phase roadmap and its twelve Quality Systems Essentials. Use the relevant phase checklists, user instructions and downloadable materials to strengthen laboratory safety, personnel, equipment, documentation, assessment and continual improvement. The GLI material is a management framework, not a product endorsement. A local TB stain guide adds the technical protocol, evidence and decisions that the framework does not prescribe.

Set the scope and governance of the guide

Begin with a controlled document owned by the TB laboratory manager and reviewed by quality, biosafety and procurement representatives. Include document ID, version, approval date, effective date, revision history and superseded versions. A useful order is: purpose and scope, product specifications, selection criteria, risk assessment, sampling and test plan, acceptance criteria, results and approval, staff training, lot release, deviation handling and scheduled review. Keep technical instructions in the standard operating procedure and make this guide the bridge between evidence and routine use. Where applicable, align it with the laboratory’s NATA accreditation and ISO 15189 quality system.

The risk assessment should cover spills, skin exposure, ventilation, waste disposal and clean-up. Consult the manufacturer’s safety data sheet, workplace procedures and applicable Australian occupational health and safety requirements. Personal protective equipment, handwashing facilities and the clean-versus-dirty workflow must be specified. The GLI’s hand hygiene and glove-use guidance can align local PPE and workflow expectations with broader laboratory infection-control practice. If phenol, methanol or other hazardous constituents are present, identify glove and eye protection, spill containment and approved waste routes under local state or territory rules.

Compare candidate stains and suppliers

Build a supplier dossier before bench testing. Ask for the exact product name, manufacturer, formulation, pack size, shelf life, storage limits, instructions for use, safety data sheets, certificates of analysis, batch traceability, recall procedures and technical support. Obtain several production lots where possible, because one bottle may not represent future deliveries. Check whether the stain is intended for brightfield acid-fast microscopy, fluorescence microscopy or both, and whether any component requires compatibility with the laboratory’s existing method.

In Australia, procurement can involve state health services, public hospital contracts, pathology providers, framework agreements or local distributors. A candidate that is inexpensive in Melbourne may cost more in Townsville once freight, small pack sizes and spoilage are included. Record landed cost, lead time and the effect of an interrupted shipment. Use a predefined score matrix for technical fit, safety, reliability, supply continuity, support and total cost. Australian teams often “book in” a delivery and “book out” a reagent lot; define those terms in the guide so inventory records remain clear.

Design a risk-based validation protocol

Decide whether the change needs verification or validation. A new lot from the same manufacturer with the same formulation may be verified against the authorised method when strong historical performance data exist. A new brand, modified formulation or change to heating, timing, water quality or reagent source calls for formal local validation. Compare the candidate with the current authorised stain or a reference method using characterised negative smears, weak and strong AFB-positive smears, mixed specimens and relevant non-tuberculous mycobacteria where appropriate. Use retained, authorised material, protect confidentiality and maintain all biosafety controls.

Predefine acceptance criteria before testing. They should cover agreement with the comparator, reliable detection of scanty AFB, absence of confusing artefacts or unexpected organisms, acceptable background, valid positive and negative controls, repeatability between operators and lots, compliance with labelled stability and storage conditions, and safe disposal. Explain what constitutes a critical failure, how many observations are required and how uncertainty around low counts will be handled. Avoid arbitrary thresholds such as “perfect agreement”; justify sample size and tolerances against the clinical risk, intended use and current quality system.

Run the staining trial under routine conditions

Use the candidate with the proposed method, microscope, water, reagent preparation and staff workflow that will be used after approval. Perform microscopy quality control and document reagent lot numbers, expiry dates, temperature records, staining times, heating conditions and deviations. Have at least two trained operators read coded slides independently, with a third experienced reader adjudicating differences. Compare day-to-day staining, repeatability between lots, carry-over between specimens, readability, background, contrast and the visibility of scanty bacilli under the intended brightfield or fluorescence method.

Training should cover product-specific handling, preparation, interpretation and reporting, not merely a demonstration by the supplier. Assess competency with practical samples and record the reader’s agreement with the reference result. Where staff also process TB liquid cultures, keep microscopy and culture competencies distinct; the GLI resource on MGIT liquid-culture training provides a useful adjacent reference for training and decontamination, but it does not replace stain-specific microscopy competency.

Analyse results and make a documented decision

Analyse all prespecified endpoints, not just the number of positive slides. Report positive and negative agreement with the comparator, confidence intervals where appropriate, invalid or unreadable rates, missed low-level positives, discrepant results and batch failures. Separate true staining-performance differences from specimen distribution, reader bias, instrument faults and procedural errors. Investigate every critical deviation and repeat affected testing only after the cause and corrective action are understood; otherwise a repeated result can hide a persistent problem.

Give the decision three possible outcomes: accepted, accepted with conditions, or rejected. Record the evidence, authorised signatory, approval date, linked risk assessment and any supplier corrective action in the quality management system. If accepted, issue the exact product and lot-release rules, update the standard operating procedure, product register and staff competency records, and retain the old authorised stock until the transition is complete. Conditional approval should identify what must be resolved before broader use rather than leaving ambiguous exceptions in bench practice.

Introduce the stain and monitor performance

Introduce the change in stages: initial bench release, supervised use by trained staff, then routine use after competency and quality-control checks pass. Keep enough current authorised stain for continuity while the first new lots are used, and establish a stock threshold that triggers ordering before interruptions affect testing. Communicate the change through shift handovers, bench notices and concise demonstrations, using the local terms staff already understand. Confirm that waste segregation, ordering, receipt checks and incident reporting work as intended under real workloads.

Monitor staining failures, invalid slides, false-positive artefacts, detection of weak positives, reagent wastage, stockouts and reader disagreements. A weekly quality-chart review can link these indicators with workload and corrective actions, while trend reviews can reveal slow deterioration before it becomes obvious at the bench. Include external proficiency testing and internal audit results, and reassess the brand after a reagent reformulation, supplier change, equipment upgrade, significant staffing shift or recurring quality problem. Record every change through document control so the guide remains useful for continual improvement rather than becoming a one-off procurement record.

Use the guide to bring the laboratory manager, quality lead, biosafety officer, procurement representative and microscopy readers into one decision. Assign an owner, schedule the trial and place the proposed criteria on the same page before samples are tested. Begin with the GLI phase checklists, document each result and seek a signed decision based on evidence that can be reproduced under Australian conditions. A carefully validated stain then becomes a dependable routine reagent, not a hopeful assumption at the bench.